TLR9 and breast carcinoma: Considering that CpG sites are known to be sites of DNA methylation that reduce gene expression when methylated, these variants could result in EA-specific TLR9 expression patterns.[47] Noteworthy, one of the synonymous variants is p.(P545 =), which is also known as rs352140 (Table 2); despite not being recognized as having a clinical link in EVS, rs352140 has been previously reported to have a protective effect against breast cancer.[25] Considering that rs352140 is significantly more common in EAs than AAs (Table 2), EAs likely benefit more from such protective effects than AAs.